Global mapping of pharmacological space
暂无分享,去创建一个
G. V. Paolini | Gaia V Paolini | Richard H B Shapland | Willem P van Hoorn | Jonathan S Mason | Andrew L Hopkins | A. Hopkins | J. Mason | W. P. Hoorn
[1] P. Andrews,et al. Functional group contributions to drug-receptor interactions. , 1984, Journal of medicinal chemistry.
[2] S. van Gestel,et al. Thirty‐three years of drug discovery and research with Dr. Paul Janssen , 1986 .
[3] William Frawley,et al. Knowledge Discovery in Databases , 1991 .
[4] W. Sneader. Drug prototypes and their exploitation , 1996 .
[5] J. Drews. Genomic sciences and the medicine of tomorrow , 1996, Nature Biotechnology.
[6] J. Drews,et al. Drug Development: The role of innovation in drug development , 1997, Nature Biotechnology.
[7] J. Drews,et al. Classic drug targets , 1997, Nature Biotechnology.
[8] G. S. Johnson,et al. An Information-Intensive Approach to the Molecular Pharmacology of Cancer , 1997, Science.
[9] Ajay,et al. Can we learn to distinguish between "drug-like" and "nondrug-like" molecules? , 1998, Journal of medicinal chemistry.
[10] Carolyn E. Begg,et al. Database Systems: A Practical Approach to Design, Implementation and Management , 1998 .
[11] Ajay,et al. Recognizing molecules with drug-like properties. , 1999, Current opinion in chemical biology.
[12] I. Kuntz,et al. The maximal affinity of ligands. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[13] S. Frye. Structure-activity relationship homology (SARAH): a conceptual framework for drug discovery in the genomic era. , 1999, Chemistry & biology.
[14] J. Wang,et al. Toward designing drug-like libraries: a novel computational approach for prediction of drug feasibility of compounds. , 1999, Journal of combinatorial chemistry.
[15] C. Lipinski. Drug-like properties and the causes of poor solubility and poor permeability. , 2000, Journal of pharmacological and toxicological methods.
[16] B. Roth,et al. The Multiplicity of Serotonin Receptors: Uselessly Diverse Molecules or an Embarrassment of Riches? , 2000 .
[17] B. Stockwell. Chemical genetics: ligand-based discovery of gene function , 2000, Nature Reviews Genetics.
[18] I. Muegge,et al. Simple selection criteria for drug-like chemical matter. , 2001, Journal of medicinal chemistry.
[19] Jörg Rech,et al. Knowledge Discovery in Databases , 2001, Künstliche Intell..
[20] I. Muegge,et al. Computational methods to estimate drug development parameters. , 2001, Current opinion in drug discovery & development.
[21] F. Lombardo,et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.
[22] A. Hopkins,et al. The druggable genome , 2002, Nature Reviews Drug Discovery.
[23] Ruedi Stoop,et al. An Ontology for Pharmaceutical Ligands and Its Application for in Silico Screening and Library Design , 2002, J. Chem. Inf. Comput. Sci..
[24] Stephen R. Johnson,et al. Molecular properties that influence the oral bioavailability of drug candidates. , 2002, Journal of medicinal chemistry.
[25] J. Proudfoot. Drugs, leads, and drug-likeness: an analysis of some recently launched drugs. , 2002, Bioorganic & medicinal chemistry letters.
[26] Walters Wp,et al. Guiding molecules towards drug-likeness. , 2002 .
[27] M. Murcko,et al. Guiding molecules towards drug-likeness. , 2002, Current opinion in drug discovery & development.
[28] Jan M. Zytkow,et al. Handbook of Data Mining and Knowledge Discovery , 2002 .
[29] W Patrick Walters,et al. Prediction of 'drug-likeness'. , 2002, Advanced drug delivery reviews.
[30] P. Shannon,et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. , 2003, Genome research.
[31] I. Muegge. Selection criteria for drug‐like compounds , 2003, Medicinal research reviews.
[32] J. Blake. Examination of the computed molecular properties of compounds selected for clinical development. , 2003, BioTechniques.
[33] R. Strausberg,et al. From Knowing to Controlling: A Path from Genomics to Drugs Using Small Molecule Probes , 2003, Science.
[34] D. Covell,et al. Mining the NCI screening database: explorations of agents involved in cell cycle regulation. , 2003, Progress in cell cycle research.
[35] B. Shoichet,et al. A specific mechanism of nonspecific inhibition. , 2003, Journal of medicinal chemistry.
[36] B. Stockwell,et al. Biological mechanism profiling using an annotated compound library. , 2003, Chemistry & biology.
[37] Dragos Horvath,et al. Neighborhood Behavior of in Silico Structural Spaces with Respect to in Vitro Activity Spaces-A Novel Understanding of the Molecular Similarity Principle in the Context of Multiple Receptor Binding Profiles , 2003, J. Chem. Inf. Comput. Sci..
[38] Dragos Horvath,et al. Predicting ADME properties and side effects: the BioPrint approach. , 2003, Current opinion in drug discovery & development.
[39] P. Leeson,et al. A comparison of physiochemical property profiles of development and marketed oral drugs. , 2003, Journal of medicinal chemistry.
[40] James B Golden,et al. Prioritizing the human genome: knowledge management for drug discovery. , 2003, Current opinion in drug discovery & development.
[41] Edgar Jacoby,et al. Annotating and mining the ligand-target chemogenomics knowledge space , 2004 .
[42] B. Roth,et al. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia , 2004, Nature Reviews Drug Discovery.
[43] A. Hopkins,et al. Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.
[44] Michael S Lajiness,et al. Molecular properties that influence oral drug-like behavior. , 2004, Current opinion in drug discovery & development.
[45] T. Insel,et al. NIH Molecular Libraries Initiative , 2004, Science.
[46] M. Vieth,et al. Kinomics-structural biology and chemogenomics of kinase inhibitors and targets. , 2004, Biochimica et biophysica acta.
[47] C. Wermuth. Selective optimization of side activities: another way for drug discovery. , 2004, Journal of medicinal chemistry.
[48] Ian A. Watson,et al. Characteristic physical properties and structural fragments of marketed oral drugs. , 2004, Journal of medicinal chemistry.
[49] Xiaoyang Xia,et al. Classification of kinase inhibitors using a Bayesian model. , 2004, Journal of medicinal chemistry.
[50] A. Hopkins,et al. Navigating chemical space for biology and medicine , 2004, Nature.
[51] Michel Dumontier,et al. CO: A chemical ontology for identification of functional groups and semantic comparison of small molecules , 2005, FEBS letters.
[52] M. Vieth,et al. Kinomics: characterizing the therapeutically validated kinase space. , 2005, Drug discovery today.
[53] D. Rogers,et al. Using Extended-Connectivity Fingerprints with Laplacian-Modified Bayesian Analysis in High-Throughput Screening Follow-Up , 2005, Journal of biomolecular screening.
[54] S. Frantz. Drug discovery: Playing dirty , 2005, Nature.
[55] David Kushner,et al. Playing Dirty , 2007, IEEE Spectrum.